Emerging therapies such as IMSA101, PNT2002 (177Lu-PNT2002), and others are expected to drive growth in the Oligometastatic Disease market in the coming years.
DelveInsight has released a new report titled “Oligometastatic Disease – Market Insights, Epidemiology, and Market Forecast 2034,” offering a comprehensive analysis of the disease, including historical and projected epidemiology and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Oligometastatic Disease market report
Some of the key facts of the Oligometastatic Disease Market Report:
-
According to DelveInsight’s patient-based forecasting model, the oligometastatic disease market in the seven major markets (7MM) was valued at approximately USD 1.9 billion in 2023, with significant growth expected through 2034 driven by increasing case numbers and the introduction of new therapies.
-
In March 2025, the FDA approved Pluvicto for earlier use in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received androgen receptor pathway inhibitors and are eligible to defer chemotherapy. Novartis is also conducting Phase III trials to assess Pluvicto in earlier disease stages, including oligometastatic prostate cancer (PSMA-DC, NCT05939414).
-
Oligometastatic disease represents an intermediate stage between localized and widespread cancer, generally involving one to five metastatic sites beyond the primary tumor.
-
In 2023, the United States accounted for roughly 40% of all oligometastatic cases within the 7MM. Common forms include oligometastatic breast, prostate, colorectal, renal cell, and non-small cell lung cancers (NSCLC). That year, the U.S. reported around 30,000 oligorecurrent cases, with NSCLC representing the largest share.
-
Currently, there are no approved therapies for oligometastatic disease. Several investigational treatments are in development, with key companies including ImmuneSensor Therapeutics (IMSA101), POINT Biopharma (PNT2002), and Novartis Pharmaceuticals (Pluvicto).
-
In 2023, the United States reported the highest number of oligometastatic cases among the 7MM, totaling approximately 117,800 cases, followed by Japan. Oligometastasis is commonly observed in breast cancer, NSCLC, hormone-naive and castration-resistant prostate cancer, head and neck cancer, colorectal cancer, pancreatic cancer, and renal cell carcinoma. In the U.S., NSCLC accounted for the largest number of cases that year.
-
The United States held the largest oligometastatic disease market share in 2023, representing about 50% of the total 7MM market.
-
Key companies actively developing therapies for oligometastatic disease include ImmuneSensor Therapeutics, POINT Biopharma, Novartis Pharmaceuticals, AstraZeneca PLC, Bristol-Myers Squibb Company, and others, aiming to enhance the treatment landscape.
-
Promising pipeline therapies include IMSA101, PNT2002 (177Lu-PNT2002), and others.
Oligometastatic Disease Overview
Oligometastatic disease describes a stage of cancer in which cells from the primary tumor spread to form a small number of metastatic lesions, usually in one or two additional sites. For instance, colon cancer may metastasize to the liver, or breast cancer may produce a few tumors in the brain.
This condition is characterized by a limited number of metastases, generally one to five distant sites beyond the original tumor. Unlike the traditional understanding that cancer spreads extensively and progressively, the oligometastatic concept suggests that certain patients may benefit from targeted local therapies aimed at controlling or potentially eradicating these restricted metastases.
Oligometastatic Disease Market Outlook
Currently, there are no approved pharmacological treatments for oligometastatic disease. Management primarily relies on local therapies such as surgery and radiotherapy, which have shown benefits in retrospective analyses and small clinical studies. Phase II trials suggest that combining definitive local interventions like stereotactic body radiotherapy (SBRT) or surgery with standard systemic therapies can improve progression-free survival (PFS) or overall survival (OS) in selected patients.
In the absence of Phase III trial evidence, treatment decisions are largely informed by multidisciplinary tumor boards, which provide personalized recommendations based on the latest research and clinical guidelines. These collaborative approaches have been associated with better outcomes, improved adherence to standard-of-care treatments, and more comprehensive care planning.
Several companies are actively developing therapies for oligometastatic disease, including ImmuneSensor Therapeutics, POINT Biopharma, Novartis, AstraZeneca, and Bristol-Myers Squibb. Although the pipeline is currently limited, a few promising candidates—such as IMSA101 (ImmuneSensor) and PNT2002 (POINT Biopharma)—are in Phase II trials and are expected to reach the market during the 2024–2034 forecast period.
Discover how the Oligometastatic Disease market is rising in the coming years
Oligometastatic Disease Emerging Drugs
-
IMSA101: ImmuneSensor Therapeutics
-
PNT2002 (177Lu-PNT2002): POINT Biopharma/Eli Lilly and Company
Scope of the Oligometastatic Disease Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Oligometastatic Disease Companies: ImmuneSensor Therapeutics, POINT Biopharma, Novartis Pharmaceuticals, AstraZeneca PLC, Bristol-Myers Squibb Company, and others
-
Oligometastatic Disease Therapeutic Assessment: Oligometastatic Disease current marketed and Oligometastatic Disease emerging therapies
-
Oligometastatic Disease Market Dynamics: Oligometastatic Disease market drivers and Oligometastatic Disease market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
-
Oligometastatic Disease Unmet Needs, KOL's views, Analyst's views, Oligometastatic Disease Market Access and Reimbursement
To know what’s more in our Oligometastatic Disease report, visit: https://www.delveinsight.com/report-store/oligometastatic-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Oligometastatic Disease Market Report:
-
Oligometastatic Disease market report covers a descriptive overview and comprehensive insight of the Oligometastatic Disease Epidemiology and Oligometastatic Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
-
The Oligometastatic Disease market report provides insights into the current and emerging therapies.
-
The Oligometastatic Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Oligometastatic Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Oligometastatic Disease market.
Got queries? Click here to know more about the Oligometastatic Disease market Landscape
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Oligometastatic Disease Patient Share (%) Overview at a Glance
5. Oligometastatic Disease Market Overview at a Glance
6. Oligometastatic Disease Disease Background and Overview
7. Oligometastatic Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Oligometastatic Disease
9. Oligometastatic Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Oligometastatic Disease Emerging Therapies
12. Oligometastatic Disease Market Outlook
13. Country-Wise Oligometastatic Disease Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Oligometastatic Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Oligometastatic Disease Market Outlook 2034
Related Reports:
Oligometastatic Disease Pipeline Insights, DelveInsight
"Oligometastatic Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oligometastatic Disease market. A detailed picture of the Oligometastatic Disease pipeline landscape is provided, which includes the disease overview and Oligometastatic Disease treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
